- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
- Interventions
- Dasatinib, Icosapent Ethyl
- Drug · Dietary Supplement
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–41
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease
- Interventions
- icosapent ethyl (IPE), gel cap placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- Omega-3 fatty acid supplement
- Dietary Supplement
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
- Interventions
- Icosapent ethyl
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 39,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Cardiovascular Disease, HIV Infection
- Interventions
- Lovaza, Placebo
- Drug
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertriglyceridemia
- Interventions
- rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Cancer Cachexia
- Interventions
- Eicosapentaenoic Acid
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Stuart, Florida • Tampa, Florida
- Conditions
- Hypertriglyceridemia
- Interventions
- warfarin, omefas, omega-3-acid ethyl esters
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Type 2 Diabetes, Coronary Artery Disease
- Interventions
- Icosapent ethyl
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Huntington Disease
- Interventions
- Ethyl-EPA (Miraxion™)
- Drug
- Lead sponsor
- Amarin Neuroscience Ltd
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
- Conditions
- Heart Failure
- Interventions
- LOVAZA (Omega-3), Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Infertility, Female, Obesity
- Interventions
- Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
- Other · Dietary Supplement · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Healthy Volunteers, Markers of Cardiovascular Risk
- Interventions
- SDA soybean oil-containing foods, High-oleic sunflower oil containing foods, Eicosapentaenoic acid
- Other
- Lead sponsor
- Monsanto Company, LLC
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- St. Petersburg, Florida • Addison, Illinois
- Conditions
- Increased Drug Resistance
- Interventions
- Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
- Interventions
- SEL, FIR, CILO, FENO, VAS
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 12
- States / cities
- Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more
- Conditions
- Bipolar Disorder, Involutional Depression, Mood Disorder
- Interventions
- Ethyl Eicosapentaenoic Acid, OmegaBrite
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colon Cancer
- Interventions
- AMR101 (VASCEPA, icosapent ethyl)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts